Gene-specific DNA methylation may mediate atypical antipsychotic-induced insulin resistance

Objectives Atypical antipsychotics (AAPs) carry a significant risk of cardiometabolic side effects, including insulin resistance. It is thought that the insulin resistance resulting from the use of AAPs may be associated with changes in DNA methylation. We aimed to identify and validate a candidate...

Full description

Saved in:
Bibliographic Details
Published inBipolar disorders Vol. 18; no. 5; pp. 423 - 432
Main Authors Burghardt, Kyle J, Goodrich, Jacyln M, Dolinoy, Dana C, Ellingrod, Vicki L
Format Journal Article
LanguageEnglish
Published Denmark Blackwell Publishing Ltd 01.08.2016
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Objectives Atypical antipsychotics (AAPs) carry a significant risk of cardiometabolic side effects, including insulin resistance. It is thought that the insulin resistance resulting from the use of AAPs may be associated with changes in DNA methylation. We aimed to identify and validate a candidate gene associated with AAP‐induced insulin resistance by using a multi‐step approach that included an epigenome‐wide association study (EWAS) and validation with site‐specific methylation and metabolomics data. Methods Subjects with bipolar disorder treated with AAPs or lithium monotherapy were recruited for a cross‐sectional visit to analyze peripheral blood DNA methylation and insulin resistance. Epigenome‐wide DNA methylation was analyzed in a discovery sample (n = 48) using the Illumina 450K BeadChip. Validation analyses of the epigenome‐wide findings occurred in a separate sample (n = 72) using site‐specific methylation with pyrosequencing and untargeted metabolomics data. Regression analyses were conducted controlling for known confounders in all analyses and a mediation analysis was performed to investigate if AAP‐induced insulin resistance occurs through changes in DNA methylation. Results A differentially methylated probe associated with insulin resistance was discovered and validated in the fatty acyl CoA reductase 2 (FAR2) gene of chromosome 12. Functional associations of this DNA methylation site with untargeted phospholipid‐related metabolites were also detected. Our results identified a mediating effect of this FAR2 methylation site on AAP‐induced insulin resistance. Conclusions Going forward, prospective, longitudinal studies assessing comprehensive changes in FAR2 DNA methylation, expression, and lipid metabolism before and after AAP treatment are required to assess its potential role in the development of insulin resistance.
Bibliography: 
Michigan Institute of Clinical and Health Research (MICHR) - No. UL1RR024986
The Rachael Upjohn Clinical Scholars
The Brain and Behavior Research Foundation
ark:/67375/WNG-81S02NGM-D
ArticleID:BDI12422
NIMH - No. R01 MH082784
University of Michigan National Institutes of Environmental Health Sciences (NIEHS) - No. P30 ES017885
istex:620154D4AC9E8C5A293B2BC8AB0D130D46955E6B
Washtenaw Community Health Organization
Chemistry Core of the Michigan Diabetes Research and Training Center - No. P30DK020572; No. and P30DK092926
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1398-5647
1399-5618
1399-5618
DOI:10.1111/bdi.12422